From the “Starting Point” to Global Compliance: Heno Bio Partners With 2Firsts to Pioneer PMTA

Business by 2Firsts
Jan.16
From the “Starting Point” to Global Compliance: Heno Bio Partners With 2Firsts to Pioneer PMTA
Heno Bio—a prominent nicotine enterprise—has partnered with leading new tobacco media and think tank 2Firsts to develop a pioneering roadmap for Premarket Tobacco Product Applications (PMTAs) under the U.S. Food and Drug Administration (FDA). This partnership not only sets a precedent for the entire industry to explore new approaches to compliance, but also underscores Heno Bio’s leadership and responsibility as the “starting point” in the new tobacco supply chain.

The “Starting Point” Enterprise: A Game-Changer in Global New Tobacco

 

Nicotine, the core raw material in next-generation products (NGPs), is commonly regarded as the supply chain’s “starting point.” Hubei Heno Biological Engineering Co., Ltd. (hereafter “Heno Bio”) holds this pivotal position through its research, development, and production of nicotine, exerting far-reaching influence across the global NGP landscape.

 

On January 9, 2025, at the 2025 NGP Global Compliance Development New Year Symposium hosted by 2Firsts, Heno Bio and 2Firsts officially announced a strategic alliance focused on compliance—instantly capturing industry-wide attention. The event’s theme, “Compliance Drives Growth,” resonates with the sector’s urgent demand for solid regulatory foundations as NGPs continue to evolve rapidly.

 

Two key messages emerged from the Symposium:

 

1. 2025 as the Starting Point: The future trajectory of the industry will hinge on robust compliance measures.

 

2. Supply Chain Empowerment: By initiating strategic action at the “starting point” of the value chain, Heno Bio aims to cascade compliance benefits across downstream stakeholders.

 

From the “Starting Point” to Global Compliance: Heno Bio Partners With 2Firsts to Pioneer PMTA
Liu Qizhou (right) and Echo Guo (left) sign the strategic cooperation agreement on behalf of Heno Bio and 2Firsts. Image courtesy of 2Firsts.

 

This partnership not only enhances Heno Bio’s commitment to regulatory standards but also leverages 2Firsts’ role as a leading global media and think tank in the NGP space, amplifying best practices and insights to a worldwide audience.

 

The World’s First Nicotine Enterprise to Publicly Announce a PMTA-TPMF Application

 

During the Symposium’s strategic partnership ceremony, Heno Bio General Manager Liu Qizhou delivered a keynote titled “Compliance Best Practices from a Nicotine Enterprise Perspective.”

 

从“原点”推动全产业链合规进程——和诺生物与2Firsts战略联手打造新型烟草供应链PMTA合规先行者范本
Liu Qizhou speaks on Heno Bio’s compliance journey at the 2025 NGP Global Compliance Development New Year Symposium. Image courtesy of 2Firsts.

 

Liu highlighted that Heno Bio was among the first batch of companies in China to secure a Tobacco Monopoly Production Enterprise License in 2022 and successfully renewed it in 2023—reflecting the firm’s longstanding dedication to regulatory adherence. Now, by publicly announcing its PMTA application in the United States, Heno Bio stands out as the world’s first nicotine enterprise to openly take this critical step, reinforcing its image as a forward-looking force in global NGP compliance.

 

从“原点”推动全产业链合规进程——和诺生物与2Firsts战略联手打造新型烟草供应链PMTA合规先行者范本
A slide from Mr. Liu Qizhou’s presentation illustrating Heno Bio’s role as a compliance leader.

 

According to 2Firsts COO Echo Guo, Heno Bio’s pioneering stance not only elevates the company’s global competitiveness but also offers valuable compliance solutions to downstream players. It serves as a real-world example of how a supply-chain leader can champion new regulatory ideas and frameworks.

 

Why PMTA Is the Global “Entry Ticket”

 

Heno Bio’s compliance strategy centers on obtaining PMTA approval in the United States—the world’s largest e-cigarette market, holding roughly one-third of global market share. Beyond its market size, the U.S. also shapes international trends in both product innovation and regulatory direction. The FDA’s PMTA (Premarket Tobacco Product Applications) system is known for its rigorous and science-based criteria, often dubbed the “gold standard” of the industry.

 

Since the FDA formalized its PMTA framework in 2021, 34 products have received Marketing Granted Orders (MGOs), primarily from major multinational tobacco corporations. Looking ahead, 2024 marks the opening phase of the FDA’s “5-Year Strategic Plan,” which merges accelerated reviews with more stringent enforcement. By 2025, most e-cigarette and NGP brands seeking entry into the U.S. market will likely face PMTA requirements as a non-negotiable step.

 

“TPMF + TPMP”: A Two-Pronged Compliance Approach

 

Although Full PMTA applications are typically filed by brand owners or manufacturers, Heno Bio—positioned at the “starting point” of the supply chain—has proactively pursued compliance through the FDA’s TPMF (Tobacco Product Master Files) and TPMP (Requirements for Tobacco Product Manufacturing Practice).

 

1. Proactive Self-Regulation
By documenting its processes and adhering to rigorous production standards, Heno Bio demonstrates its scientific and technological strengths in meeting regulatory benchmarks.

 

2. Downstream Enablement
Once Heno Bio’s nicotine-related master files are approved, downstream brands can reference Heno Bio’s TPMF in their own PMTA submissions (with authorization), eliminating redundant testing and paperwork. This can significantly reduce both compliance costs and time-to-market.

 

Building a Supply Chain Blueprint for PMTA

 

How the “Starting Point” Accelerates the Entire Value Chain

 

As the global new tobacco market continues to expand and regulations tighten, every sector node—from research and development to sales—must integrate compliance measures. The Heno Bio–2Firsts alliance underscores the strategic advantage of initiating compliance at the “starting point,” ultimately benefiting the entire supply chain.

 

Heno Bio’s fortification of regulatory standards signals a call to action for its upstream suppliers to ensure legal, safe, and high-quality raw material sourcing. This move further reassures downstream stakeholders, offering greater confidence in product safety and regulatory clarity. Such an impact has the potential to transform the market, paving the way for a more stable and sustainable future for NGPs worldwide.

 


 

About HENO

 

Hubei Heno Biological Engineering Co., Ltd. is one of the first batch of natural nicotine production enterprises in the country to obtain the "Tobacco Monopoly Production Enterprise License", and the first domestic enterprise to apply for the raw material production permit with the natural nicotine extraction process route. It has obtained the "Drug Production License" issued by the Hubei Provincial Drug Administration, is a national-level specialized, refined, unique and innovative giant enterprise, a nicotine production enterprise with CANS laboratory nicotine testing capabilities, and a customs advanced certification (AEO) enterprise. The company has drafted the "Production, Processing and Technical Control Specifications for (1-Methyl-2-(3-pyridyl)pyrrolidine)", filling the global standard gap in the production, processing and technical control of natural nicotine. The company has built a safe, environmentally friendly, green and 5G smart park in Baiyangping Industrial Park Chemical Zone in Enshi, Hubei, with an annual capacity to process more than 60,000 tons of tobacco waste and a nicotine production capacity of more than 600 tons.
 

Company's official website:https://www.henonicotine.com/about-us_d1

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Philip Morris International launches IQOS ILUMA i "Leaf Green" Limited Edition in South Korea, with pre-sales starting September 4th
Philip Morris International launches IQOS ILUMA i "Leaf Green" Limited Edition in South Korea, with pre-sales starting September 4th
Philip Morris International Korea announced the launch of the limited edition "Leaf Green" color of IQOS ILUMA i and ILUMA i ONE, and will start pre-sales in IQOS direct stores and official malls nationwide from September 4, with prices of US$68 and US$45 respectively.
Sep.05 by 2FIRSTS.ai
Observation | The penetration rate of MEMS-integrated microphones is on the rise, and their stability advantages are driving the industry's popularization
Observation | The penetration rate of MEMS-integrated microphones is on the rise, and their stability advantages are driving the industry's popularization
The 6th Vape Industry Chain Exhibition was held in Shenzhen, 2Firsts observed that MEMS microphones are gradually gaining widespread application in the industry due to their advantages such as high temperature resistance, water resistance and oil resistance. With the increase in production capacity, their prices have become comparable to those of traditional products. Institutions predict that by 2031, the global market sales of MEMS microphones for e-cigarettes will reach 4.91 billion yuan, wit
Aug.28 by 2FIRSTS.ai
The U.S. Department of Justice and FDA seized 2.1 million e-cigarettes and 12 distributors and retailers were sued
The U.S. Department of Justice and FDA seized 2.1 million e-cigarettes and 12 distributors and retailers were sued
Recently, the U.S. Department of Justice and the FDA announced a joint crackdown on illegal e-cigarettes, seizing over 2.1 million unauthorized e-cigarette products from five distributors and six retailers in seven states. The companies involved had previously received warnings from the FDA but continued to sell products without market approval. This operation was jointly carried out by multiple government departments, and civil injunction lawsuits have been filed against 12 related companies an
Sep.30 by 2FIRSTS.ai
The U.S. FDA has launched a pilot program for PMTA review of nicotine pouches to expedite the approval process and enhance regulatory efficiency
The U.S. FDA has launched a pilot program for PMTA review of nicotine pouches to expedite the approval process and enhance regulatory efficiency
In Sept 2025, the US FDA launched a nicotine pouch PMTA pilot to boost review efficiency, streamline processes and uphold strict scientific standards. Based on the "tobacco product health risk continuum" concept, it shortens cycles by focusing on key product factors and enhancing real-time communication with applicants. The FDA also urges child-resistant packaging to tackle kids’ accidental exposure, emphasizes scientific review for new tobacco products, and has approved 20 nicotine pouches so f
Sep.19 by 2FIRSTS.ai
Research Abstract|Months After Flavored Tobacco Ban, More Than Half of Vape Shops in California Remain Noncompliant
Research Abstract|Months After Flavored Tobacco Ban, More Than Half of Vape Shops in California Remain Noncompliant
The study evaluated early compliance with California’s flavored tobacco sales ban (SB 793). Between April and July 2023, the research team conducted field observations at 400 vape retailers, focusing on the availability of flavored disposable e-cigarettes and JUUL pods. Results showed that about 50.3% of stores were still selling flavored products in violation of the ban, including 53.2% of disposable vape retailers and 30.9% of JUUL pod retailers.
Sep.01 by 2FIRSTS.ai
Imperial Responds to 2Firsts: Disappointed by FDA Denial of blu Product
Imperial Responds to 2Firsts: Disappointed by FDA Denial of blu Product
2Firsts interviewed Imperial Brands on FDA’s blu denial. ITG Brands responded with disappointment, vowing to pursue a fair, science-based review.
Aug.22